Growth Factors
Tesamorelin
GHRH analog
Tesamorelin (trans-3-hexenoyl-GHRH(1-44))
Research context
Tesamorelin is a full-length GHRH(1-44) analogue with a trans-3-hexenoyl group at the N-terminus, which published characterisation associates with resistance to DPP-4 degradation. Research examines GHRH receptor binding and pituitary secretion endpoints.
Common assays: GHRH receptor binding · Pituitary GH secretion · Enzymatic stability
Specification
| Designation | GHRH analog |
|---|---|
| Full name | Tesamorelin (trans-3-hexenoyl-GHRH(1-44)) |
| Sequence | trans-3-hexenoyl-GHRH(1-44) — 44-residue analogue with N-terminal acyl modification |
| CAS number | 218949-48-5 |
| Molecular formula | C221H366N72O67S |
| Molecular weight | 5135.86 g/mol |
| Formats | 10 mL Vial · 15 mL Nasal Spray · 15 mL Oral Spray |
| Solubility | Bacteriostatic water, sterile water |
| Storage | Lyophilised: 2–8 °C, protected from light. Reconstituted: 2–8 °C. |
| Current lot | TES10N1125 → |
Published literature
Selected peer-reviewed references describing research involving this compound. Listed for reference only; inclusion is not a claim about any outcome.
- Falutz J, Allas S, Blot K, et al.Metabolic effects of a growth hormone-releasing factor in patients with HIVNew England Journal of Medicine · 2007 Find on PubMed ↗
Common questions
How does tesamorelin differ from CJC-1295?
Tesamorelin is the full 44-residue GHRH sequence with an N-terminal acyl modification; CJC-1295 is the shorter 29-residue fragment with four internal substitutions. Both target the same receptor by different stabilisation strategies.
Same pathway
Related compounds
CJC-1295
GHRH analog
A tetrasubstituted analogue of growth hormone-releasing hormone (1-29), studied in pituitary secretion research.
CJC-1295 / Ipamorelin
GH Blend
A prepared blend pairing a GHRH analogue with a selective ghrelin receptor secretagogue.
IGF-1 LR3
Insulin-like growth factor-1 LR3
An 83-residue IGF-1 analogue engineered for reduced binding-protein affinity.